93 e-Letters

published between 2007 and 2010

  • clinical endpoints in RA RCTs
    Maarten Boers

    Dear Editor, Verstappen et al are to be congratulated on their 'CAMERA' strategy trial. However, they have chosen not to report the results expressed in the Disease Activity Score (DAS or DAS28). In addition, the international RA core set agreed to in 1992 was not fully applied because physician global assessment was not measured. This is a pity because it precludes calculation of ACR reponse. The lack of both DAS and ACR re...

    Show More
  • What is the best DMARD agent for refractory FMF?
    Daniel G. Arkfeld

    Dear Editor, It is with great interest that I read the article "Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra" by Kuijk et al. Previously, our group reported on the successful treatment of FMF with secondary AA amyloid with the monoclonal anti-TNF agent Infliximab(reference 1). In this case, there was an additional benefit of complete resolution of proteinuria as well as resol...

    Show More
  • Long-term effects of etanercept treatment on lipid profile in patients with rheumatoid arthritis
    Bruno Seriolo

    Dear Editor, We have read with great interest the article by Peters et al. concerning the changes on lipid profile during infliximab and corticosteroid treatment in patients with rheumatoid arthritis (RA) (1). Recently, we performed a similar longitudinal study over time using a different TNF blocker – namely etanercept. In this prospective study 22 RA female patients were analyzed. Patients received during the study etan...

    Show More
  • Anti-TNFalpha treatment decreases procoagulant activity in patients with rheumatoid arthritis
    Piotr Gluszko

    Dear Editor,

    In their interesting review, Dixon W.G. and Symmons D.P.M (1) discuss the role of TNF alpha and other factors, which may contribute to the increased cardiovascular morbidity in patients with rheumatoid arthritis (RA). The Authors support a hypothesis that TNF alpha blockade may reduce development of atherosclerosis in RA.

    There is also a growing body of evidence that TNF alpha and other inflammatory...

    Show More
  • Response to Hjardem Elisabeth, et al article Ann Rheum Dis 2007; 66: 1184-1189
    Paul Emery

    To the editor,

    We read with interest the article by Hjardem E et al which reported the experiences of switching between TNF-antagonists from the Danish patient registry, DANIBO. We would like to draw the authors’ attention to data published from our group 2 years ago which both highlights some aspects relevant to the current report and which provides some insights into the mechanisms involved. Non-response is seen...

    Show More
  • Is monoarthritis of the knee really a paraneoplastic syndrome?
    John P. Livoni MD, MPH

    Dear Editor,

    This is a response to the article by Cantini et al suggesting that monoarthritis of the knee may herald non small-cell lung cancer. The authors found that 1.7% of patients with monoarthritis of the knee were found to have non-small-cell lung cancer. All of their patients with lungcancer were middle-aged heavy smokers. I would like to point out that a number of studies (1,2) have measured the prevalence of...

    Show More
  • Treatment of PAH associated with connective tissue disease
    Omar A. Minai

    Dear Editor, I read with interest the manuscript, by Girgis et al (1) on the role of sitaxsentan in the treatment of patients with pulmonary arterial hypertension associated with connective tissue diseases. The main conclusion is that sitaxsentan, a selective endothelin-A receptor antagonist, produced a significant improvement in six-minute walk distance, functional class, and quality of life in this group of patients.

    Show More
  • Tapering of steroids in Synthetase syndrome
    Able Lawrence

    Dear Editor, It was fascinating to read the letter on the use of Rituximab in synthetase syndrome. We taper steroids only gradually in patients with dermatomyositis to prevent relapse and more so in patients with synthetase syndrome in whom we usually start methotrexate from the beginning. The tapering schedule of steroids in the index patient which came down to 10mg in 3 months seems to be overly rapid from our experience. W...

    Show More
  • PHA concentration in IGRA assays
    Christopher J Granger

    Dear Editor, In the article by Matulis et al, published online on 20 July 2007 the authors state in their discussion that “Compared with the ELISA test used in our study the IFN-gamma ELISPOT test was previously reported to have lower rates of indeterminate results (1). These differences may, among other reasons, be explained by differences in the concentrations of the mitogen PHA between the two test systems”. Can the authors...

    Show More
  • Real characterization and follow up of histiocytosis bone lesions by ultrasonography
    Mahamoud M Gabal

    Dear Editor, plain X-ray films will demonstrate the bony defect and its margin whether it is sclerotic or not. In that lesions due to excessive bone marrow infiltration and soft tissue formation , the soft tissue formed is directly proportional to the bone marrow infiltration and disease activitynot to the size of the bone defect. The accurate parameter to follow up the bone marrow infiltration or recovery is to follow up t...

    Show More